MARKET

APRE

APRE

Aprea Therapeutics, Inc.
NASDAQ
0.9101
-0.0001
-0.01%
After Hours: 0.9399 +0.0298 +3.27% 18:04 12/18 EST
OPEN
0.9100
PREV CLOSE
0.9102
HIGH
0.9398
LOW
0.9100
VOLUME
59.59K
TURNOVER
--
52 WEEK HIGH
5.00
52 WEEK LOW
0.9000
MARKET CAP
5.74M
P/E (TTM)
-0.4251
1D
5D
1M
3M
1Y
5Y
1D
Advancing APR-1051 in HPV-Positive Cancers and Extended Cash Runway Underpin Aprea Therapeutics Buy Rating and $5 Target
TipRanks · 1h ago
Aprea Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 13h ago
Aprea Therapeutics Price Target Cut to $5.00/Share From $20.00 by HC Wainwright & Co.
Dow Jones · 13h ago
Aprea Therapeutics price target lowered to $5 from $20 at H.C. Wainwright
TipRanks · 14h ago
APREA THERAPEUTICS, INC. <APRE.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $5 FROM $20
Reuters · 14h ago
BRIEF-Aprea Therapeutics CEO Issues Letter To Shareholders Highlighting Outlook For 2026
Reuters · 15h ago
Aprea Therapeutics CEO issues letter to shareholders
TipRanks · 17h ago
Aprea Therapeutics Updates 2025 Progress, Cash Runway To Support Operations Through Q1 2027
Benzinga · 17h ago
More
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.

Webull offers Aprea Therapeutics Inc stock information, including NASDAQ: APRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APRE stock methods without spending real money on the virtual paper trading platform.